AChE and BuChE inhibitors have been developed and used to treat Alzheimer’s disease by boosting cholinergic neurotransmitter activity in the brain, thereby reducing AD symptoms [6,7]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.